BioStem TechnologiesBSEM +4.22%49 Days Payable is 374.25 as of Sep. 2025, which is 56% above its 10-year median of 239.31. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 706 Biotechnology companies, BioStem Technologies ranks better than 70.82% on this metric.
The historical rank and industry rank for BioStem Technologies's Days Payable or its related term are showing as below:
BSEM'
s Days Payable Range Over the Past 10 Years
Min: 81.78 Med: 239.31 Max: 4254.7
Current: 306.8
During the past 13 years, BioStem Technologies's highest Days Payable was 4254.70. The lowest was 81.78. And the median was 239.31.
BSEM's Days Payable is ranked better than 70.82% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs BSEM: 306.80
BioStem Technologies's Days Payable
increased
from Sep. 2023 (275.58) to Sep. 2025 (374.25).
It may suggest that BioStem Technologiesdelayed paying its suppliers.
BioStem Technologies Days Payable Related Terms
BioStem Technologies Days Payable Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioStem Technologies's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a Days Payable of 374.25 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioStem Technologies and its competitors. This is 56% above median its historical median of 239.31. Over the past decade, BioStem Technologies' Days Payable has ranged from 81.78 to 4,254.70. According to the industry distribution chart, BioStem Technologies ranks #206 out of 706 companies in the Biotechnology industry, placing it in the top 29.2%.
Is BioStem Technologies' Days Payable too high?
BioStem Technologies' current Days Payable of 374.25 is 56% above median its 10-year median of 239.31. Over the past 10 years, this metric has ranged from a low of 81.78 to a high of 4,254.70. The Biotechnology industry median Days Payable is 113.56. BioStem Technologies' value of 374.25 is 229.6% above this industry median. Based on the distribution chart, BioStem Technologies ranks #206 out of 706 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Days Payable compare to TCRX and BYSI?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #206 out of 706 companies for Days Payable. This puts BioStem Technologies in the upper half of its industry. The industry median Days Payable is 113.56. BioStem Technologies' value of 374.25 is 229.6% above this benchmark. Historically, BioStem Technologies' own Days Payable has ranged from 81.78 to 4,254.70 over the past decade. While the company's 10-year median is 239.31 vs. the industry median of 113.56, BioStem Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current Days Payable of 374.25 is 229.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Days Payable is 374.25, which is 56% above median its own 10-year median of 239.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.59 — trading 97.4% below its estimated fair value. The current Days Payable is 374.25, which is 56% above median its 10-year median of 239.31 and 229.6% above the Biotechnology industry median of 113.56. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Days Payable is 374.25 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.59 is trading 97.4% below its estimated GF Value™ of $139.96.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
Days Payable: 374.25 (56% above median its 10-year median of 239.31)
GF Value™: $139.96 vs. price of $3.59 (97.4% below fair value)
Industry Position: 229.6% above the Biotechnology median (#206 of 706)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
